文献速递临床微生物分子诊断

核酸扩增检测对产气荚膜梭菌相关疾病的诊断准确性:系统综述与荟萃分析

Diagnostic Accuracy of Nucleic Acid Amplification-Based Assays for Clostridium perfringens-Associated Diseases: a Systematic Review and Meta-analysis.
PubMed 文献 · J Clin Microbiol · 2020-08-24

该系统综述与荟萃分析评估了核酸扩增检测(NAAT)在临床腹泻样本中检测产气荚膜梭菌的诊断性能,共纳入5项研究817份样本。NAAT对免疫 assay 的敏感性为0.53、特异性0.97,对微生物培养的敏感性为0.31、特异性0.95,特异性均≥95%,但敏感性不足,尚不能替代传统参考标准,可与培养联合使用。

要点

  • NAAT检测产气荚膜梭菌特异性高(≥95%),但敏感性有限(0.31-0.53)。
  • NAAT诊断准确性优于免疫 assay 和微生物培养,但不足以单独替代传统标准。
  • NAAT可与微生物培养联合使用,尤其适用于传统检测不可行时。

核心结论

  • NAAT诊断准确性相对不足,不能作为单一检测替代传统参考标准。
  • NAAT可与微生物培养联合应用,因其出结果时间短且适用于传统检测不可行的情况。
  • 尚需更大样本量的研究进一步验证。

研究设计与样本

  • 从2632条引文中纳入5项合格研究,共817份样本。
  • 3项研究(n=695)比较NAAT与微生物培养,另3项研究(n=322)比较NAAT与免疫 assay。

主要发现

  • NAAT对免疫 assay:敏感性0.53(95%CI 0.35-0.7),特异性0.97(95%CI 0.95-0.99),PLR 23.2(95%CI 3.49-153.98),NLR 0.25(95%CI 0-245.28),DOR 74.11(95%CI 2.11-2593.7)。
  • NAAT对微生物培养:敏感性0.31(95%CI 0.22-0.41),特异性0.95(95%CI 0.93-0.97),PLR 11.56(95%CI 3.87-34.6),NLR 0.57(95%CI 0.27-1.21),DOR 18.1(95%CI 4.83-67.8)。
  • NAAT合并特异性相对于所用参考标准始终≥95%。
  • 对样本条件、基因靶标、研究设计和参考标准的荟萃回归及亚组分析未能解释诊断效率的异质性(P>0.05)。

临床怎么用

  • NAAT可作为产气荚膜梭菌相关疾病的辅助检测,尤其适用于需要快速结果或传统检测不可行的场景。
  • 因敏感性不足,NAAT阴性结果不能完全排除感染,建议结合微生物培养。

局限性

  • 纳入研究数量较少(仅5项),样本量有限。
  • 诊断效率存在未解释的异质性(P>0.05)。
  • 需要更大样本量的进一步研究支持结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Timely and accurate methods for detecting Clostridium perfringens-associated diseases (CPAD) are crucial to improve patient care. A number of studies have evaluated the accuracy of nucleic acid amplification tests (NAAT) in detecting CPAD, but decisive results about their effectiveness have not been reported. We conducted a meta-analysis to evaluate the diagnostic performance of NAAT for detecting C. perfringens in clinical diarrheal samples. Five databases including PubMed, Embase, Scopus, Web of Science, and the Cochrane library were systematically probed for studies published before 6 December 2019. From 2,632 citations, we identified five eligible studies comprising 817 samples. Three studies (n = 695 samples) compared NAAT with a microbiological culture while the other three studies (n = 322 samples) compared NAAT with an immunoassay. NAAT revealed higher diagnostic accuracy against immunoassay (sensitivity, 0.53 [95% confidence interval [CI], 0.35 to 0.7]; specificity, 0.97 [95% CI, 0.95 to 0.99]; positive likelihood ratio [PLR], 23.2 [95% CI, 3.49 to 153.98]; negative likelihood ratio [NLR], 0.25 [95% CI, 0 to 245.28]; diagnostic odds ratio [DOR], 74.11 [95% CI, 2.11 to 2,593.7]) than microbiological culture (sensitivity, 0.31 [95% CI, 0.22 to 0.41]; specificity, 0.95 [95% CI, 0.93 to 0.97]; PLR, 11.56 [95% CI, 3.87 to 34.6]; NLR, 0.57 [95% CI, 0.27 to 1.21]; DOR, 18.1 [95% CI, 4.83 to 67.8]). NAAT pooled specificity was consistently ≥95% against that of applied reference standards. A meta-regression and subgroup analysis of sample condition, gene target, study design, and reference standards could not explain the heterogeneity (P > 0.05) in the diagnostic efficiency. The analysis has demonstrated that the diagnostic accuracy of NAAT is relatively insufficient to replace traditional reference standards as a single diagnostic test. NAAT can be applied in combination with microbiological culture because of the advantage of time to result and in scenarios where traditional tests are not feasible. Further investigations in this direction with larger sample sizes are still warranted to support our findings.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Chen K, Ahmed S, Sheng YJ, et al. Diagnostic Accuracy of Nucleic Acid Amplification-Based Assays for Clostridium perfringens-Associated Diseases: a Systematic Review and Meta-analysis. J Clin Microbiol. 2020. PMID: 32404484. doi:10.1128/JCM.00363-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。